Press Releases

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find

Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Salt Lake City USA , Oxford UK , Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed

OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler SALT LAKE CITY , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent  C. difficile infection, and IND clearance for a Phase 1/2 trial in biomarker-enriched solid tumors and lymphoma (Target RBM39),

Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Salt Lake City, UT , Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin's innate glucosyltransferase in order to inhibit the toxin produced by C.

SALT LAKE CITY and SUNNYVALE, Calif., Oct. 21, 2024 /PRNewswire/ -- Recursion, a leading TechBio company decoding biology to radically improve lives, and Google Cloud today announced an expanded collaboration leveraging Google Cloud's technologies to support Recursion's drug discovery platform.

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY , Sept.

SALT LAKE CITY , Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place